Company Profiles

driven by the PitchBook Platform

Aura Biosciences

Description

Developer of a new class of therapies created to revolutionize the treatment of cancer. The company's advanced platform is based on viral nanoparticle conjugates (VNCs) that deliver potent cytotoxic therapies that can selectively eliminate cancer cells through ophthalmic laser activation in the back of the eye, without damaging the retina or other ocular structures, enabling physicians to treat cancer more selectively, effectively and safely and eliminate the need for invasive procedures that carry significant morbidity.

2009

Founded

PRIVATE

Status

1-10

Employees

Later Stage VC

Latest Deal Type

$44M

Total Amount Raised

10

Investors

Description

Developer of a new class of therapies created to revolutionize the treatment of cancer. The company's advanced platform is based on viral nanoparticle conjugates (VNCs) that deliver potent cytotoxic therapies that can selectively eliminate cancer cells through ophthalmic laser activation in the back of the eye, without damaging the retina or other ocular structures, enabling physicians to treat cancer more selectively, effectively and safely and eliminate the need for invasive procedures that carry significant morbidity.

Website:

www.aurabiosciences.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Delivery

Primary Office

85 Bolton Street Cambridge, MA 02140United States
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Aura Biosciences's full profile, request a free trial.

Aura Biosciences Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Aura Biosciences Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Aura Biosciences Investors (10)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Advent Life SciencesVenture CapitalMinority000 0000000 0000
Alexandria Real Estate EquitiesReal EstateMinority000 0000000 0000
Chiesi VenturesCorporate Venture CapitalMinority000 0000000 0000
Droia Oncology VenturesVenture CapitalMinority000 0000000 0000
Henri TermeerAngel (individual)Minority000 0000000 0000
Advent Life Sciences Venture Capital
Alexandria Real Estate Equities Real Estate
Chiesi Ventures Corporate Venture Capital
Droia Oncology Ventures Venture Capital
Henri Termeer Angel (individual)

Aura Biosciences Executive Team (12)

NameTitleBoard
Seat
Contact
Info
Elisabet de los Pinos Ph.DFounder, Chief Executive Officer, President & Board Member
Mike WyzgaChief Financial Officer
Alison LawtonChief Operating Officer
Andrew Russell Ph.DDirector, Manufacturing
John MacDougall Ph.DDirector, Research
Elisabet de los Pinos Ph.D Founder, Chief Executive Officer, President & Board Member
Mike Wyzga Chief Financial Officer
Alison Lawton Chief Operating Officer
Andrew Russell Ph.D Director, Manufacturing
John MacDougall Ph.D Director, Research

Aura Biosciences Board Members (12)

NameRepresentingRoleSinceContact
Info
Alan Walts Ph.DSelfExecutive Chairman000 0000
Arthur PappasChiesi VenturesExecutive000 0000
Dale Pfost Ph.DAdvent Venture PartnersGeneral Partner000 0000
Elisabet de los Pinos Ph.DAura BiosciencesFounder, Chief Executive Officer, President & Board Member000 0000
Henri TermeerSelfBoard Member000 0000
Alan Walts Ph.D Executive Chairman Self
Arthur Pappas Executive Chiesi Ventures
Dale Pfost Ph.D General Partner Advent Venture Partners
Elisabet de los Pinos Ph.D Founder, Chief Executive Officer, President & Board Member Aura Biosciences
Henri Termeer Board Member Self
Request full access to PitchBook